Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct;59(5):102871.
doi: 10.1016/j.transci.2020.102871. Epub 2020 Jul 3.

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

Affiliations
Case Reports

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

Ayşe Karataş et al. Transfus Apher Sci. 2020 Oct.

Abstract

Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first identified in Wuhan, China; and spread all over the world. Reverse-transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2 usually returns to negative in 20 days post-infection, but prolonged positivity has been reported up to 63 days. A case whose viral shedding lasted 60 days is reported from China. Herein we report a patient with a history of autologous stem cell transplantation (ASCT) for lymphoma whose RT-PCR test remained positive for SARS-CoV-2 for 74 days. The prolonged RT-PCR positivity, despite convalescent plasma infusion, may suggest that the given antibodies may be ineffective in terms of viral clearance. In patients with hematological malignancies or immunosuppression, such as ASCT, may lead to prolonged viral shedding, and strict isolation is warranted for long-term SARS-CoV-2 infection control.

Keywords: Autologous stem cell transplantation (ASCT); COVID-19; Convalescent plasma; Lymphoma; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Temporal Changes in (CT) (positive control) - (CT) (patient). (CT) of the consequent samples were as follows 26.75, 28.13, 28.13, 29.45, 37.8 and 34.7 at respective time points. (*) CT → Cycle Threshold (**) HCQ → Hydroxychloroquine

References

    1. Neurath M.F. Covid-19 and immunomodulation in IBD. Gut. 2020;69(7):1335–1342. doi: 10.1136/gutjnl-2020-321269. - DOI - PMC - PubMed
    1. Ritchie A.I., Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020;395(10230):1111. doi: 10.1016/S0140-6736(20)30691-7. - DOI - PMC - PubMed
    1. Zhu L. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: A summary of 10 confirmed cases in wuhan, china. Eur Urol. 2020;77(6):748–754. doi: 10.1016/j.eururo.2020.03.039. - DOI - PMC - PubMed
    1. Kuderer N.M. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 doi: 10.1016/S0140-6736(20)31187-9. - DOI - PMC - PubMed
    1. Chen L., Xiong J., Bao L., Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi: 10.1016/S1473-3099(20)30141-9. - DOI - PMC - PubMed

Publication types